Clinical Trials Directory

Trials / Completed

CompletedNCT00458991

rhGH Therapy on Hepatic Drug Metabolism

Recombinant Human Growth Hormone Therapy and Drug Metabolism

Status
Completed
Phase
Study type
Observational
Enrollment
9 (actual)
Sponsor
University of Louisville · Academic / Other
Sex
All
Age
4 Years – 14 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to understand the effect of rhGH therapy on hepatic drug metabolism in children with idiopathic growth hormone deficiency.

Detailed description

Growth Hormone (GH) deficiency is a prominent cause of short stature, affecting approximately 14,000 children in the US. Although a single study has demonstrated reduces CYP1A2 activity following Gh replacement therapy, the effect of GH on the most abundant phase 1 biotransformation pathways (e.g. CYP2D6 and CYP3A4) remain largely uncharacterized. This information gap exists largely due to the lack of sufficiently safe, specific and non-invasive methods appropriate for the longitudinal evaluation of enzyme activity in young children. We can overcome these problems by employing validated phenotyping methods using caffeine, a commonly ingested dietary substance and dextromethorphan, a safe, non-sedating over the counter anti-tussive agent. Application of these methods will permit us to identify, characterize and describe the isoform-specific effects of rhGH on major phase 1 hepatic drug biotransformation pathways, thereby addressing this information gap with minimal risk to children.

Conditions

Interventions

TypeNameDescription
DRUGDextromethorphan and CaffeineAll subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic "probes" (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH.

Timeline

Start date
2001-06-01
Primary completion
2008-09-01
Completion
2008-09-01
First posted
2007-04-11
Last updated
2017-04-27

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00458991. Inclusion in this directory is not an endorsement.